After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...

On Friday, 2Seventy Bio Inc (TSVT) stock saw a modest uptick, ending the day at $4.93 which represents a slight increase of $0.17 or 3.57% from the prior close of $4.76. The stock opened at $4.83 and ...

Daina Graybosch, an analyst from Leerink Partners, reiterated the Buy rating on 2seventy bio (TSVT – Research Report). The associated ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by ...

Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...

On Wednesday, 2Seventy Bio Inc (TSVT) stock saw a decline, ending the day at $4.32 which represents a decrease of $-0.45 or -9.43% from the prior close of $4.77. The stock opened at $4.32 and touched ...

Older adults treated for cancer had double the risk of cardiovascular (CV) events, including stroke, as compared with those ...

Despite being open for over a year across 18 countries, the trial managed to recruit only 10% of its target population.

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on 2seventy bio (TSVT – Research Report), with a ...

This news brief covers various health-related updates including Washington state's abortion pill stockpile, EPA regulations on fluoridated water, radiation exposure in spaceflight, BioAge Labs' IPO, ...

NEW YORK – Bristol Myers Squibb and 2seventy bio said on Wednesday they are discontinuing enrollment in the Phase III KarMMa-9 study evaluating maintenance treatment with CAR T-cel therapy Abecma ...